117 related articles for article (PubMed ID: 21351448)
1. [Effect of CYP3A and P-glycoprotein on the absorption of buagafuran in rat intestinal lumen].
Sheng L; Tan W; Hu JP; Chen H; Li Y
Yao Xue Xue Bao; 2010 Jan; 45(1):43-8. PubMed ID: 21351448
[TBL] [Abstract][Full Text] [Related]
2. [Effect of P-glycoprotein on the absorption of buagafuran in rat intestinal lumen].
Li E; Li Y
Yao Xue Xue Bao; 2008 Apr; 43(4):361-5. PubMed ID: 18664196
[TBL] [Abstract][Full Text] [Related]
3. A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
Tan W; Chen H; Zhao J; Hu J; Li Y
J Pharm Pharm Sci; 2008; 11(3):97-105. PubMed ID: 18801310
[TBL] [Abstract][Full Text] [Related]
4. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.
Zhao G; Huang J; Xue K; Si L; Li G
Eur J Pharm Sci; 2013 Nov; 50(3-4):429-39. PubMed ID: 23981337
[TBL] [Abstract][Full Text] [Related]
5. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
Cummins CL; Salphati L; Reid MJ; Benet LZ
J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
[TBL] [Abstract][Full Text] [Related]
6. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
[TBL] [Abstract][Full Text] [Related]
7. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Dufek MB; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
[TBL] [Abstract][Full Text] [Related]
8. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
[TBL] [Abstract][Full Text] [Related]
9. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism.
Mudra DR; Borchardt RT
J Pharm Sci; 2010 Feb; 99(2):982-98. PubMed ID: 19746412
[TBL] [Abstract][Full Text] [Related]
10. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
Dufek MB; Knight BM; Bridges AS; Thakker DR
Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
[TBL] [Abstract][Full Text] [Related]
12. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Aug; 94(8):1694-704. PubMed ID: 15986467
[TBL] [Abstract][Full Text] [Related]
13. The Consequence of Drug-Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices.
Li M; de Graaf IA; Siissalo S; de Jager MH; van Dam A; Groothuis GM
Drug Metab Dispos; 2016 May; 44(5):683-91. PubMed ID: 26932816
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies.
Yang C; Zhang T; Li Z; Xu L; Liu F; Ruan J; Liu K; Zhang Z
Toxicol Appl Pharmacol; 2013 Dec; 273(3):561-8. PubMed ID: 24120885
[TBL] [Abstract][Full Text] [Related]
16. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.
Ni L; Yu X; Yu Q; Chen X; Jia L
Drug Metab Lett; 2008 Aug; 2(3):163-8. PubMed ID: 19356088
[TBL] [Abstract][Full Text] [Related]
18. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
19. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Usansky HH; Hu P; Sinko PJ
Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics.
Kaddoumi A; Fleisher D; Heimbach T; Li LY; Cole S
J Pharm Sci; 2006 Feb; 95(2):435-45. PubMed ID: 16381015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
